Charles River Laboratories (CRL) 2026 stock analysis: the three-pillar preclinical CRO model spanning research models, DSA safety assessment, and CDMO manufacturing, the razor-and-consumable repeat-demand engine, leverage to a recovering biotech funding cycle, NHP primate supply and regulatory risk, and a peer comparison against IQVIA, ICON, Medpace, and Inotiv.
Jeil Pharmaceutical group (Jeil Pharma Holdings, KRX: 271980) 2026 stock analysis: a low-margin base of distributing multinational in-licensed drugs, layered with a re-rating option from subsidiary Onconic Therapeutics' P-CAB reflux drug zastaprazan (Jaqbo) — domestic launch plus a China out-licensing royalty. Bull case, competition versus K-CAB and Fexuclue, holding-company structure, and what global investors should watch.
INSM (Insmed) stock outlook for 2026. A qualitative deep dive into the Arikayce revenue base for NTM lung disease, the brensocatib bronchiectasis catalyst, the TPIP pulmonary hypertension pipeline, and the commercialization-transition and cash-burn risks that define this late-stage biotech.
Viatris (VTRS) 2026 stock outlook. A qualitative deep dive into the Pfizer Upjohn-Mylan merger, the debt paydown and dividend story, brand-revenue decline offset by complex generics and biosimilars, EpiPen's fading pricing power, and the key risks.
A qualitative 2026 outlook on Chong Kun Dang (KRX: 185750), the Korean pharma whose K-CAB-led incremental drugs fund a diversifying novel-drug pipeline. We unpack the cash-cow base, licensing-out and royalty optionality, operating margins and R&D, drug-price pressure, peer positioning, and what global investors should monitor each quarter.
HK inno.N (KRX 195940) 2026 stock outlook. A qualitative deep dive into K-CAB (tegoprazan), Korea's homegrown P-CAB reflux drug and its competitive moat, the global licensing-out model, US clinical ambitions, the Condition hangover brand and IV-fluid base business, plus single-product dependence and drug-pricing risk for international investors.